Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-thymocyte globulin + basiliximab + mycophenolate mofetil + tacrolimus
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This combination is a multi-drug immunosuppressive regimen used primarily in the setting of islet cell transplantation for patients with Type 1 Diabetes Mellitus. It consists of induction therapy with anti-thymocyte globulin (ATG), a T-cell depleting polyclonal antibody, and basiliximab, a monoclonal antibody targeting the IL-2 receptor (CD25). Maintenance immunosuppression is provided by tacrolimus, a calcineurin inhibitor, and mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase (IMPDH). The regimen is designed to prevent allograft rejection by targeting multiple pathways of T-cell activation and proliferation. It has been investigated in clinical trials led by the Vrije Universiteit Brussel (AZ-VUB) to evaluate the long-term survival and function of transplanted beta cells.
- Other names
- ATG + basiliximab + MMF + tacrolimus
02
Targets
CN (Calcineurin)FKBP1AIL2RA (Interleukin-2 receptor alpha subunit)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on anti-thymocyte globulin + basiliximab + mycophenolate mofetil + tacrolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-thymocyte globulin + basiliximab + mycophenolate mofetil + tacrolimus.